CAMBRIDGE, Mass. , May 25, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the resignation of Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development, effective June 9, 2017 . Dr. Al-Wakeel , who has been in his role with Merrimack since
Completes asset sale to Ipsen for up to $1.025 billion in cash and potential milestones payments; declares special cash dividend to stockholders of $140 million<br>Initiates Phase 1 clinical study of antibody-directed nanotherapeutic (ADN) MM-310; data expected in 2018<br>Conference call at 8:30 am ET today
CAMBRIDGE, Mass. , May 2, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its first quarter 2017 investor conference call and webcast at 8:30 am ET on Wednesday, May 10, 2017. The call will cover an update on Merrimack's recent
CAMBRIDGE, Mass. , April 17, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that Daryl Drummond , Ph.D. has been appointed Head of Research. Dr. Drummond , an expert and pioneer in the field of nanotherapeutics, has held various leadership roles at Merrimack,
CAMBRIDGE, Mass. , April 5, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $140 million on the company's common stock. This special dividend will be paid from the proceeds of the
Completes Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen<br>Merrimack Plans to Return $140 Million to Stockholders through Special Cash Dividend<br>To Set Record Date for Payment of Special Cash Dividend in Due Course
CAMBRIDGE, Mass. , March 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack") announced that, at its Special Meeting of Stockholders held today, its stockholders voted to approve the asset sale with Ipsen S.A. under which Merrimack will: Sell to Ipsen its first
Presentations to include data on MM-310, a novel antibody-directed nanotherapeutic targeting EphA2, and istiratumab (MM-141), a monoclonal bispecific antibody that acts as a tetravalent inhibitor of IGF1-R and HER3
CAMBRIDGE, Mass. , March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals , Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the
